Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akero Therapeutics Inc
(NQ:
AKRO
)
26.61
-0.41 (-1.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akero Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
June 05, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
June 01, 2023
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Recap: Akero Therapeutics Q3 Earnings
November 04, 2022
Akero Therapeutics (NASDAQ:AKRO) reported its Q3 earnings results on Friday, November 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
September 14, 2022
Via
Benzinga
$9.6M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
May 24, 2023
Although US stocks closed lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
May 16, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
March 29, 2023
From
Akero Therapeutics
Via
GlobeNewswire
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
March 22, 2023
The battle pits 89bio and Akero in nonalcoholic steatohepatitis.
Via
Investor's Business Daily
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023
Via
Benzinga
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
January 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
20 Favorite Biotech & Medical Stocks For 2023
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year.
Via
Talk Markets
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
December 22, 2022
Via
Benzinga
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
December 21, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
December 08, 2022
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 10, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
November 07, 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category
From
Akero Therapeutics
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
November 25, 2022
On Friday, 68 companies reached new 52-week highs.
Via
Benzinga
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 04, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
September 30, 2022
Gainers
Via
Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
September 30, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 14, 2022
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.